Form 4: Halozyme Therapeutics SVP, General Counsel, Reports Stock Option and Restricted Stock Unit Awards

Mark Howard Snyder, SVP and General Counsel of Halozyme Therapeutics, reports the acquisition of stock options and restricted stock units.

Summary

• On February 23, 2024, Mark Howard Snyder, the SVP and General Counsel of Halozyme Therapeutics, Inc., was granted options to purchase 29,064 shares of common stock at an exercise price of $40.56.
• These options vest one-fourth on February 23, 2025, and then 1/48th monthly thereafter.
• Snyder also received 28,045 restricted stock units (RSUs) on February 23, 2024.
• These RSUs vest one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
• Following these transactions, Snyder directly owns 29,064 options and 28,045 RSUs.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of stock options and RSUs to a key executive aligns their interests with those of the shareholders.
• The vesting schedules for both the options and RSUs incentivize long-term performance and retention.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules suggest a commitment to long-term value creation.

Industry Context

Stock option and RSU grants are common compensation practices for executives in publicly traded companies, aligning their interests with shareholders and incentivizing performance.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and grant sizes are generally comparable to industry norms for executives at similar levels.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates